Artiva Biotherapeutics (NASDAQ:ARTV) CEO Sells $244,315.16 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) CEO Fred Aslan sold 27,116 shares of the business’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $9.01, for a total transaction of $244,315.16. Following the completion of the sale, the chief executive officer directly owned 1,535,082 shares of the company’s stock, valued at $13,831,088.82. The trade was a 1.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Artiva Biotherapeutics Stock Down 7.3%

Shares of ARTV traded down $0.67 during midday trading on Tuesday, hitting $8.55. The company had a trading volume of 844,679 shares, compared to its average volume of 581,930. The company’s 50 day moving average price is $8.32 and its 200 day moving average price is $5.65. The stock has a market cap of $211.36 million, a price-to-earnings ratio of -2.42 and a beta of 2.86. Artiva Biotherapeutics, Inc. has a 52 week low of $1.47 and a 52 week high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its earnings results on Friday, May 8th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.07). Equities analysts anticipate that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Dimensional Fund Advisors LP bought a new position in Artiva Biotherapeutics in the 1st quarter worth about $131,000. Sanctuary Advisors LLC bought a new position in Artiva Biotherapeutics in the 1st quarter worth about $139,000. Simplify Asset Management Inc. bought a new position in Artiva Biotherapeutics in the 1st quarter worth about $150,000. OMERS ADMINISTRATION Corp bought a new position in Artiva Biotherapeutics in the 4th quarter worth about $91,000. Finally, Marshall Wace LLP bought a new position in Artiva Biotherapeutics in the 4th quarter worth about $341,000.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on ARTV. Wall Street Zen downgraded shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Sunday. Wedbush boosted their price objective on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Friday, April 24th. Cantor Fitzgerald boosted their price objective on shares of Artiva Biotherapeutics from $10.00 to $40.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Finally, Needham & Company LLC boosted their price objective on shares of Artiva Biotherapeutics from $18.00 to $41.00 and gave the company a “buy” rating in a research report on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Artiva Biotherapeutics has an average rating of “Moderate Buy” and a consensus target price of $39.00.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.